乳糖-N-新四糖 Lacto-N-neotetraose (LNnT)

13007-32-4

C26H45NO21

707.63

1mg

100mg

LNnT;BETA-D-GAL-[1->4]-BETA-D-GLCNAC-[1->3]-BETA-D-GAL-[1->4]-D-GLC;GAL-BETA1,4GLCNA-CBETA1, 3GAL-BETA1, 4GLC;LACTO-N-NEOTETRAOSE;NLCOSE;NLCOSE4;lacto-N-neo-tetraose from human milk;N-[(2S,3R,4R,5S,6R)-2-[(2R,3S,4S,5R,6S)-3,5-dihydroxy-2-(hydroxymethyl)-6-[(2R,3R,4R,5R)-1,2,4,5-tetrahydroxy-6-oxohexan-3-yl]oxyoxan-4-yl]oxy-4-hydroxy-6-(hydroxymethyl)-5-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-3-yl]acetamide

2-8°C

Core Structures Type 2

Galβ1-4GlcNAcβ1-3Galβ1-4Glc 
Lacto-N-neotetraose / LNnT / neo-LNT linked to BSA      5mg ,25mg ,100mg
G Boehm and B Stahl. Oligosaccharides. 2003. In Functional dairy products. p203-243. T Mattila-Sandholm and M Saarela, Editors. Boca Raton: CRC Press.

Lacto-N-neotetraose / LNnT / neo-LNT   [13007-32-4]
Galβ1-4GlcNAcβ1-3Galβ1-4Glc
C26H45NO21
FW 707.62
5 mg, 25 mg  
100 mg, 1 g, 5 g, please call 021-60498804

All of the HMOs are an alyzed by Nuclear Mass Spectrometry (NMR) and High Performance Anion Exchange Chromatography (HPAEC) for structure validation and determination of their level of purity.

Minor human milk oligosaccharides
GLY0353  PI   Blood group A antigen tetraose type 5
GLY037-1 PII  Blood group A antigen hexaose type 1